Chromosome Analysis is a technique where the chromosomes from cells are visualized under a microscope during metaphase, the stage during cell division when chromosomes are condensed, to analyze the total number and structure of the chromosomes. Staining with Giemsa dye results in a specific banding pattern of light and dark stripes, known as G-banding, and allows identification of each chromosome.
DNA Sequencing deciphers the precise order of the adenine, cytosine, guanine, and thymine nucleotides within a DNA sample. Next-Generation Sequencing (NGS) platforms are highly automated and deliver large scale DNA sequence data with high speed and accuracy.
FISH is a cytogenetic technique that uses a fluorescently labeled probe to detect the location or absence of a target DNA sequence directly on a fixed slide preparation of chromosomes.
Flow cytometry is a technique for counting, sorting, and analyzing thousands of microscopic particles per second by passing a suspension past an electronic detection apparatus. Flow cytometry can be used for cell counting, cell sorting, and biomarker detection, as well as measuring total DNA, newly synthesized DNA, and gene expression. This technique allows simultaneous multiparametric analysis of physical and/or chemical characteristics.
Immunohistochemistry is the detection of expression levels and distribution of antigens (e.g. proteins) in a cell or tissue section (usually frozen or paraffin embedded tissues) using antibodies bound to the target that can be visualized through staining.
ISH is a hybridization technique using a labeled complementary DNA or RNA strand as a probe to bind to a specific DNA or RNA sequence target to localize the target within a chromosome or tissue.
Nucleic acid microarray analysis combines robotics, chemistry, computer science, and biology to study thousands of genes simultaneously. Thousands of spotted samples, DNA, cDNA, or oligonucleotides, are known as probes (with known identity). Probes are immobilized on a solid support, such as a microscope glass slides, silicon chips, or nylon membranes. Nucleic acid microarrays allow analysis of gene expression and discovery, and mutation analysis of many thousands of genes in a single reaction quickly and efficiently.
PCR is a molecular biology technique where a DNA template sequence is exponentially amplified from a single copy by a thermal cycling process. Through repeated cycles of heating and cooling, the target DNA is replicated using a thermo stable DNA polymerase and DNA primers complementary to the target region.
Chairman of the Board of Directors and Chief Executive Officer
Chief Science Officer and Director of BioPharma Operations
Chief Technology Officer and Director, Informatics
Chief Information Officer
Chief Medical Officer and Director of Research and Development
Chief Financial Officer
Executive Vice President of Finance, Chief Compliance Officer, and Board Member
Chief Growth Officer
Vice President, Human Resources
Vice President, BioPharma and Business Development
Director of Finance and Principal Accounting Officer
Dr. Albitar has served as Chief Medical Officer and Director of Research and Development since 2012. Prior to NeoGenomics, Dr. Albitar served as the Medical Director of Hematopathology and Oncology and Chief of R&D for Hematopathology and Oncology, Quest Diagnostics. Prior to joining Quest Diagnostics, Dr. Albitar held various faculty positions at The University of Texas MD Anderson Cancer Center and rose to the position of tenured Full Professor in the Departments of Leukemia and Laboratory Medicine/Pathology. He held the position of Director of Molecular Laboratory and Leukemia Section at MD Anderson Cancer Center at the time of leaving MD Anderson. Dr. Albitar was trained in Anatomic and Clinical Pathology at Brown University in Providence, RI and in Hematopathology at the University of Pennsylvania. He did his post-doctoral training in Genetics at the Genetic Department of Howard Hughes Medical Institute at the University of Pennsylvania. Dr. Albitar received his medical degree from Damascus Medical School in Damascus, Syria.
Mr. VanOort has served as the Chairman of the Board and Chief Executive Officer of NeoGenomics since 2009. Previously, he served as Chairman of the Board, Executive Chairman and Interim Chief Executive Officer from 2009 to 2009. From 1995 to 1999, he served as the Senior Vice President, Operations for Quest Diagnostics, Incorporated. During this period, Quest Diagnostics grew to approximately $1.5 billion in annual revenue through both organic growth and mergers and acquisitions. From 1982 to 1995, Mr. VanOort served in various positions at Corning Incorporated and ultimately held the position of Executive Vice President and CFO of Corning Life Sciences, Inc. In 1995, Corning Incorporated spun off Corning Life Sciences, Inc. into two companies, Quest Diagnostics and Covance, Inc. Mr. VanOort serves as a member of the board of directors of several privately held companies. In addition, since 2000, Mr. VanOort is the co-owner of Vision Ace Hardware, LLC, a retail hardware chain. Mr. VanOort is a graduate of Bentley University.
Mr. Cotton serves as Vice President, BioPharma and Business Development for NeoGenomics. Mr. Cotton started at Clarient Diagnostic Services in 2013, and joined NeoGenomics as a result of the NeoGenomics acquisition of Clarient. Previously, Mr. Cotton served as Zone Vice President at Siemens Diagnostics where he directed the sales and technical operations and played a key role in the execution of a national Performance Culture initiative. Mr. Cotton previously served as Vice President, Sales for Viracor-IBT. Prior to joining Viraco-IBT, Mr. Cotton held various roles at Beckman Coulter, Inc., including successful efforts for medical diagnostic sales of chemistry, hematology, immunoassay, automation and IT products in the South Central United States and leading the flow cytometry team for diagnostic and research sales across the United States as National Sales Director. Mr. Cotton received his bachelor’s degree in biology from Jacksonville State University and his MBA from Keller Graduate School, DeVry University.
Dr. Brodie is the Chief Scientific Officer and Director of BioPharma Operations. Also, Dr. Brodie serves in numerous roles including as the Laboratory Director of the Fort Myers and Tampa Facilities and Director of Molecular Genetics and Cytogenetics. Prior to joining NeoGenomics in 2011, Dr. Brodie served as Senior Director of Cytogenetics, Assistant Director of Molecular Genetics, and Scientific Director of Maternal Serum Screening at Specialty Laboratories/Quest Diagnostics in Valencia, CA. Dr. Brodie trained pathology residents in genetic testing at both Loma Linda University Medical Center, where he served as the Affiliate Rotation Director, and University of Southern California, Keck School of Medicine, where he served as a Clinical Assistant Professor of Pathology. Prior to joining Quest Diagnostics, he held a variety of research and clinical positions at the National Institutes of Health, University of New Mexico School of Medicine, and UCLA David Geffen School of Medicine. Dr. Brodie received his genetics training at the UCLA/Cedar-Sinai Medical Center medical genetics training program in Los Angeles, CA. He received his Ph.D. from UNM School of Medicine and completed Clinical Genetics training in Cytogenetics and Molecular Genetics at UCLA. Dr. Brodie is Board Certified by the American Board of Medical Genetics in these specialties and holds Director licenses in Florida, California, and New York. Throughout his career, Dr. Brodie has held various research and clinical positions at the NIH, UNM and UCLA, and comes to us after directing high throughput testing in Cytogenetics, FISH, Molecular Genetics, and Oncology for Quest Diagnostics, Nichols Institute. He is also a CAP approved inspector.
Mr. Cardoza has served as Chief Financial Officer of NeoGenomics since 2009. Prior to that, Mr. Cardoza served as the Chief Financial Officer of Protocol Global Solutions, Inc., a privately held international marketing company, from 2008 to 2009. Mr. Cardoza also served as the Controller of Protocol Global Solutions from 2006 to 2008. From 1991 to 2006, Mr. Cardoza was employed by Quest Diagnostics Inc. in a number of positions, including Controller, Central Region from 2001 to 2006. At Quest Diagnostics, Inc., Mr. Cardoza was responsible for overseeing all the financial operations of the Central Region, which had revenue of over $1.2 billion in 2006. Prior to his time with Quest Diagnostics Inc., he worked for Sony Music Entertainment Inc. and the Continental Grain Company in various financial roles. Mr. Cardoza received his bachelor’s degree from Syracuse University in finance and accounting and received his MBA from Michigan State University.
Mark Machulcz serves as the Vice President, Operations at NeoGenomics. Mr. Machulcz started at Clarient Diagnostic Services in 2011 to help with expansion efforts, and joined NeoGenomics as a result of the NeoGenomics acquisition of Clarient. Previously, Mr. Machulcz served as Executive Vice President of Operations for PLUS Diagnostics, Inc. and oversaw its California and New Jersey laboratory operations and support staff. Mr. Machulcz previously directed pan-India operations for a unit of Quest Diagnostics Incorporated. Prior to that position, he served as a Director of Clinical and Anatomic Pathology Operations for a unit of Quest. During his tenure at Quest Diagnostics, he improved its anatomic pathology service levels and productivity, and implemented six sigma projects that contributed to more efficient lab operations. Mr. Machulcz received his bachelor's degree in Medical Technology from St. Louis University and his MBA from Johns Hopkins University.
Mr. Ross has served as Chief Information Officer of NeoGenomics since 2013. Mr. Ross brings over 25 years of technology leadership experience while most recently serving as the Vice President of Technology for Chico’s FAS, Inc., from 2003 to 2013. Chico’s is a multi-branded retailer, with more than 1,550 stores, an award winning eCommerce and Direct-to-Consumer offering, and $2.6 billion in annual revenue. In addition to retail, Mr. Ross has extensive technology experience in the manufacturing, engineering, and financial sectors, having served in a variety of management and consulting roles with Motorola, DirecTV, American Express, and Target. Mr. Ross received his bachelor’s degree from New Mexico State University.
Mr. Shovlin joined NeoGenomics in 2014 as the Chief Operating Officer, and now serves as the Chief Growth Officer. Mr. Shovlin oversees sales, marketing, managed care, business development, biopharma services, and customer care. Previously, he served as Chief Development Officer for Bostwick Laboratories, a leading provider of anatomic pathology testing services. From 2005 to 2011, he served in several positions of increasing responsibility, ultimately as President and Chief Executive Officer for Aureon Biosciences, Inc., a venture-backed diagnostics company focused on developing novel and proprietary prostate cancer tests. Mr. Shovlin also served as Executive Director of Anatomic Pathology and as Director of Managed Care for Quest Diagnostics from 2003 until 2005, and held sales leadership positions at Dianon Systems from 1997 until 2003. Mr. Shovlin served as a Captain, Infantry Officer, in the United States Marine Corps from 1992 until 1997 where he served as a Platoon Commander and Company Commander with 1st Battalion 4th Marines and as an Instructor and Staff Platoon Commander at The Basic School. He received his bachelor’s degree from Pennsylvania State University, and his MBA in Finance from Rutgers University.
Mr. Hoyt serves as the Chief Technology Officer and Director, Informatics for NeoGenomics. Mr. Hoyt started at Clarient Diagnostic Services in 2015, and joined NeoGenomics as a result of the Clarient acquisition. Mr. Hoyt has more than 17 years of information technology experience in the healthcare industry. Previously, Mr. Hoyt served as the Global IT M&A Manager for GE Healthcare Life Sciences and Operations Manager for the Business Intelligence Center of Excellence at GE Healthcare. Mr. Hoyt joined GE as a member of the Information Technology Leadership Program in 1999 and progressed through assignments in Service and Supply Chain before becoming a certified Master Blackbelt in 2010 and a graduate of GE's Experienced Information Management Program in 2013.
Mr. Jones has served as a director of NeoGenomics since 2003, as Executive Vice President of Finance since 2009, and as Chief Compliance Officer since 2013. Mr. Jones served as Chief Financial Officer of the Company from 2003 until 2009. He is a Managing Director in Medical Venture Partners, LLC, a venture capital firm established in 2003 for the purpose of making investments in the healthcare industry. Mr. Jones is also the founder and Chairman of the Aspen Capital Group and has been President and Managing Director of Aspen Capital Advisors since 2001. Prior to that, Mr. Jones was a chief financial officer at various public and private companies and was a Vice President in the Investment Banking Group at Merrill Lynch & Co., Inc. Mr. Jones received his bachelor’s degree in Computer Engineering from the University of Michigan in 1985 and his MBA from the Wharton School of the University of Pennsylvania in 1991. He also serves as Chairman of the Board of T3 Communications, Inc. and serves on the Board of Directors of XG Sciences, Inc.
Mrs. Balliet joined NeoGenomics in 2008 as Director, Human Resources, and was appointed as Vice President, Human Resources in 2015. Mrs. Balliet has managed Human Resources as the Company grew from 100 employees to more than 800 employees. She is responsible for all areas of Human Resources, including recruiting, training, compensation, incentive plans, and organizational development. Mrs. Balliet received her Bachelor of Science degree in Psychology and her Master of Science degree in Business Management from the University of Florida.
Mr. Weidig III has served as Director of Finance and Principal Accounting Officer since 2012. Mr. Weidig served as the Company’s Corporate Controller from 2007 until 2012. Prior to that, from 2005 to 2007 he was a Division Controller for Meritage Homes Corporation in Fort Myers, Florida, and prior to that from 1999 to 2005 he worked in public accounting for a local firm in Fort Myers, Florida and for PricewaterhouseCoopers in Boston, Massachusetts. Mr. Weidig earned his Bachelor of Science degree in Business Administration from Merrimack College. Mr. Weidig holds an active CPA license with the state of Massachusetts.